In order to implement the requirements of “carrying out skills training around professional inspector team construction” of leading Party group of the CFDA, to promote the capacity of inspectorate, and improve the professional skills and comprehensive quality of the inspectors, the Third Experts’ Forum of CFDI was held successfully according to the work plan of CFDI Academic Committee on May 11, 2017. Li Haiyan, the director Drug Clinical Trial Institution of Peking University Third Hospital was invited in this expert forum, and made the lecture entitled “Overview of Common Diseases and Main Treatment Drugs of Cardiovascular System”.

Director Li has very rich clinical experiences on the treatment of blood vessel internal medicine diseases, especially the interventional diagnosis and treatment of coronary heart disease, treatment of hypertension, hyperlipidemia and cardiac failure as well as rescue of cardiovascular medicine critical emergency diseases, etc. And at the same time, she also has undertaken clinical research on new drugs for over 20 years and has completed several clinical trial researches. At this Experts’ Forum, she indicated the symptoms of common diseases of cardiovascular system, such as hypertension, hyperlipidemia, coronary disease and cardiac failure, etc. and main treatment drugs in details, and described the entire process and concern emphasis of clinical trial on combination of the specific clinical trial cases of cardiovascular drugs. Her speech systematically summarized and also highlighted key points, included specific disease symptoms and drug use interpretation and also shared the practical clinical trial experience, which has important guidance meaning for relevant inspection work.

Over 260 people of CFDI, the Chinese Pharmacopoeia Commission, Beijing Drug Certification Management Center and 15 provincial drug inspectorate from the whole country synchronously watching through video system participated in the training. ‍